Table 2.
Steady-state cardiovascular responses to hypoxic submaximal exercise following 18 h of hypoxic exposure
| Placebo | Sildenafil | Acetazolamide | |
|---|---|---|---|
| SaO2 (%) | 88.1 ± 0.7 (84.5–94.4) | 88.7 ± 0.7 (83.9–92.1) | 89.3 ± 0.8b (82.1–94.3) |
| HR (bpm) | 128 ± 4 (109–158) | 133 ± 5a (104–163) | 129 ± 5c (99–158) |
| SBP (mmHg) | 144 ± 5 (118–178) | 140 ± 5a (119–177) | 140 ± 6 (93–171) |
| DBP (mmHg) | 71 ± 6 (58–99) | 67 ± 6 (53–95) | 70 ± 5 (62–89) |
| MAP (mmHg) | 95 ± 5 (80–122) | 92 ± 5a (75–122) | 93 ± 5 (79–110) |
SaO2, arterial oxygen saturation; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure
a
Placebo versus sildenafil
b
Placebo versus acetazolamide
c
Sildenafil versus acetazolamide